The aim of this pilot project, launched jointly with three large healthcare centers in Serbia – the University Clinical Centre of Serbia, the University Children’s Clinic Tiršova, and Zemun Hospital – and in cooperation with the innovative Japanese pharmaceutical company Takeda, is to reduce the complexity of Fabry disease diagnosis by employing modern AI techniques. The goal is to shorten the time to an accurate diagnosis, alleviate pressure on the healthcare system, and consequently redirect treatment costs to appropriate innovative therapy. This project is implemented in collaboration with the AI in Healthcare & Lifescience group at the Institute.